Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EGX-EA19
- Development stage
- Preclinical
- Lead developer
- EUGENEX Biotechnologies
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
EGX-EA19 is a biosimilar candidate of guselkumab, a human monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23). Developed by EUGENEX Biotechnologies, EGX-EA19 is designed to inhibit the interaction of IL-23 with its cell surface receptor, thereby neutralizing the pro-inflammatory activities of this cytokine. IL-23 is a key driver in the pathogenesis of several immune-mediated inflammatory diseases, including plaque psoriasis and psoriatic arthritis, by promoting the maintenance and expansion of Th17 cells. As a biosimilar, EGX-EA19 is engineered to be highly similar in structure, function, and clinical performance to the reference product, Tremfya, providing a potentially more cost-effective therapeutic option for patients with moderate-to-severe inflammatory conditions.
- Other names
- Guselkumab biosimilar
02
Targets
IL23A (Interleukin-23 p19 Subunit)
Beyond the preview
Go deeper on EGX-EA19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EGX-EA19.